Inlexisertib

CAS 2543673-19-2

MF C26H36F3N7O2,  535.62

4-(3-((2-((2-ethyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)propyl)-1,4-oxazepan-5-one

4-[3-[[2-[2-ethyl-4-(4-methylpiperazin-1-yl)anilino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]propyl]-1,4-oxazepan-5-one

serine/ threonine kinase inhibitor, antineoplastic, DCC 3116, JM2ZTM8S7S

Inlexisertib is an orally bioavailable inhibitor of the serine/threonine-protein kinase ULK 1 and 2, with potential antineoplastic activity. Upon oral administration, inlexisertib targets and binds to ULK1/2. This inhibits cancer autophagy, which mutant RAS cancer cells use for their survival, and results in tumor cell death. ULK1/2 mediates the autophagocytotic process and is often upregulated in cancers, especially in mutant RAS cancers. Autophagy plays a key role in a tumor cell proliferation and survival, and mediates tumor cell resistance.

• A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced MalignanciesCTID: NCT05957367Phase: Phase 1/Phase 2Status: RecruitingDate: 2025-06-05
• A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid TumorsCTID: NCT04892017Phase: Phase 1/Phase 2Status: RecruitingDate: 2025-05-06

SYN

US11530206

https://patents.google.com/patent/US11530206B2/en

PAT

Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof

Publication Number: JP-7593947-B2

Priority Date: 2019-05-10

Grant Date: 2024-12-03

• PHENYLAMINOPYRIMIDINE AMIDE INHIBITORS OF AUTOPHAGY AND METHODS OF THEIR APPLICATIONPublication Number: HR-P20231730-T1Priority Date: 2019-05-10
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: US-12071432-B2Priority Date: 2019-05-10Grant Date: 2024-08-27
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: CN-118878519-APriority Date: 2019-05-10
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: CN-118878520-APriority Date: 2019-05-10
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: CN-118930524-APriority Date: 2019-05-10
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: AU-2020275392-B2Priority Date: 2019-05-10Grant Date: 2023-09-14
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: CN-114127057-BPriority Date: 2019-05-10Grant Date: 2024-07-12
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: EP-3966207-B1Priority Date: 2019-05-10Grant Date: 2023-11-01
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: EP-4342469-A2Priority Date: 2019-05-10
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: ES-2966807-T3Priority Date: 2019-05-10Grant Date: 2024-04-24
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: EP-3966207-A1Priority Date: 2019-05-10
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: KR-20220008873-APriority Date: 2019-05-10
• Phenylaminopyrimidine amide autophagy inhibitor and how to use itPublication Number: JP-2022531801-APriority Date: 2019-05-10
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: US-11530206-B2Priority Date: 2019-05-10Grant Date: 2022-12-20
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: US-2023039712-A1Priority Date: 2019-05-10
• Combination of dcc-3116 and mapkap pathway inhibitors for use in the treatment of cancerPublication Number: WO-2024050351-A1Priority Date: 2022-09-02
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: US-2020354352-A1Priority Date: 2019-05-10
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: WO-2020231806-A1Priority Date: 2019-05-10
• Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereofPublication Number: AU-2020275392-A1Priority Date: 2019-05-10
• Phenylaminopyrimidine amide autophagy inhibitor and method of usePublication Number: CN-114127057-APriority Date: 2019-05-10

PAT

WO-2024050351

PAT

 WO-2020231806

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020231806&_cid=P12-MHCSWS-98394-1

AS ON JUNE2025 4.45 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

……

/////////Inlexisertib, serine/ threonine kinase inhibitor, antineoplastic, DCC 3116, JM2ZTM8S7S